A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats - PubMed (original) (raw)
. 2007 Mar;192(3):595-603.
doi: 10.1677/JOE-06-0045.
Affiliations
- PMID: 17332527
- DOI: 10.1677/JOE-06-0045
A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats
Yuichi Kikuchi et al. J Endocrinol. 2007 Mar.
Abstract
Fasudil, a Rho-kinase inhibitor, may improve insulin signaling. However, its long-term effect on metabolic abnormalities and its preventive effect on diabetic nephropathy are still unknown. We assessed these effects of fasudil in insulin-resistant diabetic rats, comparing them with those of an angiotensin II receptor blocker, olmesartan. Male Otsuka Long-Evans Tokushima fatty (OLETF) and Long-Evans Tokushima Otsuka, non-diabetic control, rats at 15 weeks of age were used. OLETF rats were randomized to receive a low or a high dose of fasudil or olmesartan for 25 weeks. To examine the therapeutic effects after the development of diabetes, OLETF rats at 30 weeks of age were given fasudil for 10 weeks. Administration of high-dose fasudil completely suppressed the development of diabetes, obesity, and dyslipidemia and increased serum adiponectin levels in OLETF rats. High-dose olmesartan also decreased hemoglobin A1c and increased serum adiponectin. There was a significant correlation between hemoglobin A1c and serum adiponectin or free fatty acid levels. The treatment with high-dose fasudil ameliorated proteinuria, glomerulosclerosis, renal interstitial fibrosis, and macrophage infiltration in OLETF rats. Olmesartan, even at the low dose, suppressed renal complications. The treatment with fasudil after the development of diabetes improved the metabolic abnormalities in OLETF rats, but could not suppress the progression of nephropathy. We conclude that the long-term treatment with fasudil prevents the development of diabetes, at least in part, by improving adipocyte differentiation in insulin-resistant diabetic rats. Early use of fasudil may prevent diabetic nephropathy.
Similar articles
- The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats.
Gojo A, Utsunomiya K, Taniguchi K, Yokota T, Ishizawa S, Kanazawa Y, Kurata H, Tajima N. Gojo A, et al. Eur J Pharmacol. 2007 Jul 30;568(1-3):242-7. doi: 10.1016/j.ejphar.2007.04.011. Epub 2007 Apr 20. Eur J Pharmacol. 2007. PMID: 17511984 - Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats.
Kikuchi Y, Imakiire T, Yamada M, Saigusa T, Hyodo T, Hyodo N, Suzuki S, Miura S. Kikuchi Y, et al. Nephrol Dial Transplant. 2005 Aug;20(8):1573-81. doi: 10.1093/ndt/gfh888. Epub 2005 May 19. Nephrol Dial Transplant. 2005. PMID: 15905195 - CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.
Koga K, Yamagishi S, Takeuchi M, Inagaki Y, Amano S, Okamoto T, Saga T, Makita Z, Yoshizuka M. Koga K, et al. Mol Med. 2002 Oct;8(10):591-9. Mol Med. 2002. PMID: 12477969 Free PMC article. - Role of intrarenal angiotensin-converting enzyme in nephropathy of type II diabetic rats.
Taniguchi M, Kim S, Zhan Y, Iwao H. Taniguchi M, et al. Hypertens Res. 2002 Mar;25(2):287-94. doi: 10.1291/hypres.25.287. Hypertens Res. 2002. PMID: 12047045 - Adiponectin: A Promising Target for the Treatment of Diabetes and Its Complications.
Begum M, Choubey M, Tirumalasetty MB, Arbee S, Mohib MM, Wahiduzzaman M, Mamun MA, Uddin MB, Mohiuddin MS. Begum M, et al. Life (Basel). 2023 Nov 16;13(11):2213. doi: 10.3390/life13112213. Life (Basel). 2023. PMID: 38004353 Free PMC article. Review.
Cited by
- ROCK (RhoA/Rho Kinase) Activation in Atrial Fibrillation: Molecular Pathways and Clinical Implications.
Proietti R, Giordani AS, Lorenzo CA. Proietti R, et al. Curr Cardiol Rev. 2023;19(3):e171122210986. doi: 10.2174/1573403X19666221117092951. Curr Cardiol Rev. 2023. PMID: 36625201 Free PMC article. - Rho-kinase inhibition ameliorates non-alcoholic fatty liver disease in type 2 diabetic rats.
Elkattawy HA, Elsherbini DM, Ebrahim HA, Abdullah DM, Al-Zahaby SA, Noser Y, Hassan AE. Elkattawy HA, et al. Physiol Res. 2022 Nov 28;71(5):615-630. doi: 10.33549/physiolres.934869. Epub 2022 Aug 31. Physiol Res. 2022. PMID: 36047723 Free PMC article. - Insight Into Rho Kinase Isoforms in Obesity and Energy Homeostasis.
Wei L, Shi J. Wei L, et al. Front Endocrinol (Lausanne). 2022 Jun 13;13:886534. doi: 10.3389/fendo.2022.886534. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35769086 Free PMC article. Review. - Rho-Kinase as a Therapeutic Target for Nonalcoholic Fatty Liver Diseases.
Sousa-Lima I, Kim HJ, Jones J, Kim YB. Sousa-Lima I, et al. Diabetes Metab J. 2021 Sep;45(5):655-674. doi: 10.4093/dmj.2021.0197. Epub 2021 Sep 30. Diabetes Metab J. 2021. PMID: 34610720 Free PMC article. Review. - Renal ROCK Activation and Its Pharmacological Inhibition in Patients With Diabetes.
Matoba K, Sekiguchi K, Nagai Y, Takeda Y, Takahashi H, Yokota T, Utsunomiya K, Nishimura R. Matoba K, et al. Front Pharmacol. 2021 Sep 7;12:738121. doi: 10.3389/fphar.2021.738121. eCollection 2021. Front Pharmacol. 2021. PMID: 34557101 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical